-
In October 2009, the FDA licensed the bivalent human papillomavirus vaccine (HPV2; Cervarix, GlaxoSmithKline) for use in females aged 10 through 25 years.
-
A nationwide survey conducted in March 2008 of 429 pediatricians and 419 family physicians in the United States with response rates of 81% and 79%, respectively, showed that 98% of pediatricians and 80% of family physicians were administering HPV vaccine in their offices.
-
Two-hundred eleven adipose biopsies were obtained from 59 patients participating in the Western Australia HIV cohort study.
-
Investigators in lausanne, switzerland cultured the noses of 405 new hospital workers for Staphylococcus aureus, then checked them again about nine months later.
-
As part of a longitudinal study of host/parasite relationships, which was initiated in two Senegalese villages in 1990 (and initially focused on malaria and tick-borne borreliosis), the potential of T. whipplei to cause infection in patients with fever of unknown etiology and negative test results for malaria was initiated in late 2008 and continued until the summer of 2009.
-
In this issue: Antiviral drugs and birth defects, bisphosphonates and esophageal cancer, naltrexone plus bupropion for weight loss, 2010-11 influenza vaccine, FDA Actions.
-
A retrospective review of CDC laboratory records identified five cases of tick-borne encephalitis (TBE) among U.S. travelers between 2000 and 2009.
-
The advisory committee on immunization practices (APIC) and the CDC have updated for the use of the 23 valent pneumococcal polysaccharide vaccine (PPSV23) for the prevention of invasive pneumococcal disease in adults.
-
With antimicrobial resistance among clinical bacterial isolates becoming a greater problem with each passing year, the need for novel antibacterial agents has become more urgent than ever.
-
In countries endemic for malaria, young children often receive empiric antimalarial therapy for febrile illness, resulting in over treatment and expense.
